During a live event, Karen Seiter, MD, discussed the role of the JAK/STAT pathway in myeloproliferative neoplasms and the use ...

Label Use of Topical Ruxolitinib in Dermatology: A Systematic Literature Review and Current Perspectives,” published in the ...

Join Drs Tania Jain and Prithviraj Bose as they discuss the available JAK inhibitors and how they use them to treat ...

Panelists discuss how managing advanced polycythemia vera requires tailored approaches beyond hydroxyurea when patients show resistance (persistent hematocrit >45%, elevated white blood cell counts, ...

Today, the U.S. Court of Appeals for the Federal Circuit (CAFC) issued a precedential decision in Incyte Corp. v. Sun ...

This week, we take a closer look at two precedential cases concerning pharmaceutical patent protections as applied to drugs in development.

WILMINGTON, DE — Incyte (Nasdaq: INCY) delivered strong first-quarter financial results for 2025, propelled by revenue growth ...

This study looked at adding an experimental drug called pelabresib to the drug ruxolitinib (Jakafi®), which is the current treatment for myelofibrosis. Both drugs are targeted therapies. Pelabresib ...

Now, let’s shift our focus to AD. and the emerging role of immune modulators in the treatment of AD. Please discuss the findings presented at AAD 2025 regarding the association of ruxolitinib ...

Ruxolitinib is recommended, within its marketing authorisation, as an option for treating acute graft versus host disease (GvHD) that has an inadequate response to corticosteroids in people 12 years ...

Ruxolitinib is a kinase inhibitor, prescribed for high-risk myelofibrosis. The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Bacillus calmette-guerin ...